GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Price-to-Tangible-Book

Immunic (Immunic) Price-to-Tangible-Book : 2.02 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Immunic Price-to-Tangible-Book?

As of today (2024-05-01), Immunic's share price is $1.29. Immunic's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.64. Hence, Immunic's Price to Tangible Book Ratio of today is 2.02.

The historical rank and industry rank for Immunic's Price-to-Tangible-Book or its related term are showing as below:

IMUX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.48   Med: 2.63   Max: 6.13
Current: 2.02

During the past 13 years, Immunic's highest Price to Tangible Book Ratio was 6.13. The lowest was 0.48. And the median was 2.63.

IMUX's Price-to-Tangible-Book is ranked better than
63.31% of 1221 companies
in the Biotechnology industry
Industry Median: 2.69 vs IMUX: 2.02

A closely related ratio is called PB Ratio. As of today, Immunic's share price is $1.29. Immunic's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.64. Hence, Immunic's P/B Ratio of today is 2.02.


Immunic Price-to-Tangible-Book Historical Data

The historical data trend for Immunic's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Price-to-Tangible-Book Chart

Immunic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.10 2.57 2.68 0.48 2.34

Immunic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.73 1.61 1.35 2.34

Competitive Comparison of Immunic's Price-to-Tangible-Book

For the Biotechnology subindustry, Immunic's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Immunic's Price-to-Tangible-Book falls into.



Immunic Price-to-Tangible-Book Calculation

Immunic's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.29/0.64
=2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Immunic Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Immunic's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunic (Immunic) Business Description

Traded in Other Exchanges
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Executives
Glenn Whaley officer: PAO and Controller C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick director 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann director IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt director, officer: CEO, President IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen director ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash director C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler officer: Chief Medical Officer 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel officer: Chief Operating Officer IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips director C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson director
Sanjay S Patel officer: Chief Financial Officer 10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi 10 percent owner C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster 10 percent owner C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV